Drug intelligence / Profile preview

phyllanthus urinaria

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral
01

Overview

Phyllanthus urinaria is an annual herbaceous plant widely distributed in tropical and subtropical regions of Asia, America, China, and the Indian Ocean islands. Traditionally used in folk medicine for conditions such as jaundice, diabetes, malaria, liver diseases (including viral hepatitis), fever, dysentery, gonorrhea, syphilis and as an abortifacient[1][4][5][8]. The plant contains a variety of bioactive compounds including flavonoids (e.g., quercetin), lignans (e.g., phyllanthine and hypophyllanthine), tannins, phenolic acids, terpenoids (including coumarins and steroids), and alkaloids[4][5]. Pharmacological studies have demonstrated hepatoprotective effects—particularly against hepatitis B virus by interfering with HBV DNA synthesis and reducing secretion of hepatitis B surface antigen—as well as anti-liver fibrosis/cirrhosis activity through regulation of hepatic stellate cells and extracellular matrix function[3][4]. Additionally it exhibits anticancer properties by inhibiting tumor proliferation and metastasis in hepatocellular carcinoma models; other reported activities include antidiabetic effects via modulation of glucose metabolism pathways; antimicrobial action against various pathogens; analgesic effects; cardioprotective benefits; fertility-modulating properties depending on dose; antioxidant activity[4][5][8]. Clinical trials for chronic viral hepatitis B have used doses ranging from 900–2 700 mg per day for up to three months with mixed results but some evidence for reduction in HBV markers[3].

Other names
chamber bittergripeweedshatterstonestonebreaker
02

Targets

HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on phyllanthus urinaria.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phyllanthus urinaria.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call